Promoting apoptosis as a strategy for cancer drug discovery.

Fesik SW
Nat Rev Cancer. 2005 5 (11): 876-85

PMID: 16239906 · DOI:10.1038/nrc1736

Apoptosis is deregulated in many cancers, making it difficult to kill tumours. Drugs that restore the normal apoptotic pathways have the potential for effectively treating cancers that depend on aberrations of the apoptotic pathway to stay alive. Apoptosis targets that are currently being explored for cancer drug discovery include the tumour-necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptors, the BCL2 family of anti-apoptotic proteins, inhibitor of apoptosis (IAP) proteins and MDM2.

MeSH Terms (12)

Animals Antineoplastic Agents Apoptosis Apoptosis Regulatory Proteins Humans Inhibitor of Apoptosis Proteins Membrane Glycoproteins Neoplasms Proto-Oncogene Proteins c-bcl-2 Proto-Oncogene Proteins c-mdm2 TNF-Related Apoptosis-Inducing Ligand Tumor Necrosis Factor-alpha

Connections (1)

This publication is referenced by other Labnodes entities:

Links